Can AI help pharmaceutical companies plan for drug shortages?

Merck KGaA, a Darmstadt, Germany-based pharmaceutical company, is hoping AI can improve its ability to predict drug shortages and plan accordingly.

The company says its current methods for forecasting supply and demand are 85% accurate, according to a new report from The Wall Street Journal, and it hopes AI can provide much more accuracy.

“The value is going to be that every single patient will receive the drug that he or she needs at the right moment,” said Alessandro DeLuca, CIO for Merck’s healthcare division, as quoted by the WSJ.

Merck is turning to TraceLink, a North Reading, Massachusetts-based supply chain company, to see if AI can make an impact. Merck plans on testing TraceLink’s cloud-based software platform later in 2019.  

Click the link below for the full story.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.